Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions

Targeting of Cathepsin S Reduces Cystic Fibrosis-like Lung Disease

Donna M. Small, Ryan R. Brown, Declan F. Doherty, Anthony Abladey, Zhe Zhou-Suckow, Rebecca J. Delaney, Lauren Kerrigan, Caoifa M. Dougan, Keren S. Borensztajn, Leslie Holsinger, Robert Booth, Christopher J. Scott, Guillermo López-Campos, J. Stuart Elborn, Marcus A. Mall, Sinéad Weldon, Clifford C. Taggart
European Respiratory Journal 2019; DOI: 10.1183/13993003.01523-2018
Donna M. Small
1Airway Innate Immunity Research (AiiR) Group, Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, Northern Ireland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ryan R. Brown
1Airway Innate Immunity Research (AiiR) Group, Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, Northern Ireland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Declan F. Doherty
1Airway Innate Immunity Research (AiiR) Group, Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, Northern Ireland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anthony Abladey
1Airway Innate Immunity Research (AiiR) Group, Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, Northern Ireland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zhe Zhou-Suckow
2Department of Translational Pulmonology, Translational Lung Research Center Heidelberg (TLRC), German Center for Lung Research (DZL), University of Heidelberg, Heidelberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rebecca J. Delaney
1Airway Innate Immunity Research (AiiR) Group, Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, Northern Ireland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lauren Kerrigan
1Airway Innate Immunity Research (AiiR) Group, Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, Northern Ireland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Caoifa M. Dougan
1Airway Innate Immunity Research (AiiR) Group, Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, Northern Ireland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Keren S. Borensztajn
3INSERM UMRS_933; Université Pierre et Marie Curie, Hôpital Trousseau, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Leslie Holsinger
4ViroBay Inc., Menlo Park, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert Booth
4ViroBay Inc., Menlo Park, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher J. Scott
5Centre for Cancer Research and Cell Biology, Queen's University Belfast, Northern Ireland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Guillermo López-Campos
6Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, Northern Ireland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. Stuart Elborn
6Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, Northern Ireland
7Respiratory Medicine, Imperial College and Royal Brompton Hospital, London, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marcus A. Mall
2Department of Translational Pulmonology, Translational Lung Research Center Heidelberg (TLRC), German Center for Lung Research (DZL), University of Heidelberg, Heidelberg, Germany
8Department of Pediatric Pulmonology and Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany
9Berlin Institute of Health (BIH), Berlin, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sinéad Weldon
1Airway Innate Immunity Research (AiiR) Group, Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, Northern Ireland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Clifford C. Taggart
1Airway Innate Immunity Research (AiiR) Group, Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, Northern Ireland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Cathepsin S (CatS) is upregulated in the lungs of patients with cystic fibrosis (CF). However, its role in CF lung disease pathogenesis remains unclear.

In this study β-epithelial Na+ channel-overexpressing transgenic (βENaC-Tg) mice, a model of CF-like lung disease, were crossed with cathepsin S null (CatS−/−) mice or treated with the CatS inhibitor VBY-999.

Levels of active CatS were elevated in the lungs of βENaC-Tg mice compared to wild-type (WT) littermates. CatS−/−βENaC-Tg mice exhibited decreased pulmonary inflammation, mucus obstruction and structural lung damage compared to βENaC-Tg mice. Pharmacological inhibition of CatS resulted in a significant decrease in pulmonary inflammation, lung damage and mucus plugging in the lungs of βENaC-Tg mice. In addition, instillation of CatS into the lungs of WT mice resulted in inflammation, lung remodelling and upregulation of mucin expression. Inhibition of the CatS target, protease-activated receptor-2 (PAR-2), in βENaC-Tg mice resulted in a reduction in airway inflammation and mucin expression indicating a role for this receptor in CatS-induced lung pathology.

Our data indicate an important role for CatS in the pathogenesis of CF-like lung disease mediated in part by PAR-2 and highlights CatS as a therapeutic target.

Footnotes

This manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.

Conflict of interest: Dr. Small has nothing to disclose.

Conflict of interest: Dr. Brown has nothing to disclose.

Conflict of interest: Dr. Doherty has nothing to disclose.

Conflict of interest: Dr. Abladey has nothing to disclose.

Conflict of interest: Dr. Delaney has nothing to disclose.

Conflict of interest: Dr. Kerrigan has nothing to disclose.

Conflict of interest: Dr. Dougan has nothing to disclose.

Conflict of interest: Dr. Borensztajn has nothing to disclose.

Conflict of interest: Dr. Holsinger reports other from Virobay, during the conduct of the study; other from Virobay, outside the submitted work.

Conflict of interest: Dr. Booth has a patent US 7,547,701 issued.

Conflict of interest: Dr. Scott reports other from Fusion Antibodies PLC, outside the submitted work; In addition, Dr. Scott has a patent Patents on antibodies for Cathepsin S licensed to Fusion Antibodies PLC.

Conflict of interest: Dr. López-Campos has nothing to disclose.

Conflict of interest: Dr. Elborn reports personal fees from Bayer, grants and personal fees from Horizion, during the conduct of the study; personal fees from Cheisi, personal fees from Polyfor, from null, outside the submitted work.

Conflict of interest: Dr. Mall reports grants from German Federal Ministry of Education and Research , during the conduct of the study; personal fees from Spyryx Biosciences, personal fees from Boehringer Ingelheim, personal fees from ProQR, personal fees from PTC Pharmaceuticals, personal fees from Arrowhead, personal fees from Pro Axis, personal fees from Bayer, personal fees from Polyphor, personal fees from Enterprise Therapeutics, personal fees from Sterna Biologicals, personal fees from Vertex Pharmaceuticals, outside the submitted work; In addition, Dr. Mall has a patent Patent on the Scnn1b-transgenic mouse with royalties paid.

Conflict of interest: Dr. Weldon reports grants from Randox, grants from Pfizer UK, outside the submitted work.

Conflict of interest: Dr. Taggart reports personal fees from Albumedix, grants from Randox, grants from Pfizer UK, outside the submitted work.

Conflict of interest: Dr. Zhou-Sukow has nothing to disclose.

This is a PDF-only article. Please click on the PDF link above to read it.

  • Copyright ©ERS 2019
PreviousNext
Back to top
View this article with LENS
Vol 57 Issue 2 Table of Contents
European Respiratory Journal: 57 (2)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Targeting of Cathepsin S Reduces Cystic Fibrosis-like Lung Disease
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Targeting of Cathepsin S Reduces Cystic Fibrosis-like Lung Disease
Donna M. Small, Ryan R. Brown, Declan F. Doherty, Anthony Abladey, Zhe Zhou-Suckow, Rebecca J. Delaney, Lauren Kerrigan, Caoifa M. Dougan, Keren S. Borensztajn, Leslie Holsinger, Robert Booth, Christopher J. Scott, Guillermo López-Campos, J. Stuart Elborn, Marcus A. Mall, Sinéad Weldon, Clifford C. Taggart
European Respiratory Journal Jan 2019, 1801523; DOI: 10.1183/13993003.01523-2018

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Targeting of Cathepsin S Reduces Cystic Fibrosis-like Lung Disease
Donna M. Small, Ryan R. Brown, Declan F. Doherty, Anthony Abladey, Zhe Zhou-Suckow, Rebecca J. Delaney, Lauren Kerrigan, Caoifa M. Dougan, Keren S. Borensztajn, Leslie Holsinger, Robert Booth, Christopher J. Scott, Guillermo López-Campos, J. Stuart Elborn, Marcus A. Mall, Sinéad Weldon, Clifford C. Taggart
European Respiratory Journal Jan 2019, 1801523; DOI: 10.1183/13993003.01523-2018
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
  • Info & Metrics
  • PDF

Subjects

  • Lung biology and experimental studies
  • CF and non-CF bronchiectasis
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Dynamics of SARS-CoV-2 shedding in the respiratory tract depends on the severity of disease in COVID-19 patients
  • Point-of-care lung ultrasound assessment for risk stratification and therapy guiding in COVID-19 patients. A prospective non-interventional study
  • Classification and effectiveness of different oxygenation goals in mechanically ventilated critically ill patients: network meta-analysis of randomised controlled trials
Show more Original article

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • CME
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Submit a manuscript
  • ERS author centre

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2021 by the European Respiratory Society